more_reports

The Latest Life Sciences Tools & Diagnostics Articles from Streetwise Reports

Tech Innovator Achieves Breakthrough Multi-Market Success

  ()
Clean technology company BioLargo Inc. (BLGO:OTCQX) announces it had a "widely successful" and "transformative" 2024 and is looking forward to more revenue growth in 2025. Read why one expert thinks investors should be doubling down on the stock.

AI Company Unlocks Breakthrough Medical Diagnostics Platform

  ()
One company being listed on Cboe Canada starting January 8 is using AI and smartphones to help patients get quick and accurate diagnosis of their sore throats, helping to battle microbial resistance that threatens the effectiveness of antibiotics worldwide.

Is This Centrally Positioned AI Healthcare Co. Set to Transform the Industry?

Contributed Opinion
  ()
Technical Analyst Clive Maund explains why he thinks Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) offers potential upside to investors.

AI Accelerates Breakthroughs in Cancer Drug Discovery

  ()
Rakovina Therapeutics Inc. (RKV:TSX.V) is advancing cancer drug discovery with its Deep Docking AI platform. Read more about their recent developments and future plans.

Transformative Moves in Harm Reduction Expanding Market Reach with New Partnerships and Acquisitions

  ()
Safe Supply Streaming Co. Ltd (SPLY:CSE; SSPLF:OTCQB; QM4:FSE) recently announced significant developments within its portfolio company, Safety Strips, and a key acquisition. Learn more about how these strategic developments aim to enhance harm reduction efforts and expand market reach.

AI Healthcare Co. With 'Bright' Outlook Closes Placement

  ()
Healthcare artificial intelligence (AI) company Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) has closed a non-brokered private placement for aggregate gross proceeds of CA$1.95 million. Find out why one analyst says the stock is a Strong Buy and worth going overweight on.

Is This AI Healthcare Stock Worth Being Overweight On?

Contributed Opinion
  ()
Technical Analyst Clive Maund explains why he thinks Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) is a Strong Buy and worth being overweight on.

Healthcare Tech Firm and Leading University to Join Forces

  ()
The parties intend to develop artificial intelligence-backed solutions to a problem in healthcare, for expanded use throughout and beyond the United Kingdom. Find out why one analyst is bullish on this company and its proprietary platform.

AI Healthcare Co. Signs Partnership With Large Regional Health Plan

Research Report
  ()
Ontrak Inc. (NASDAQ: OTRK) announced it had signed a two-year strategic partnership with a large, northeast regional health plan focused on the plan's New York State members. This development comes as the company continues to rebuild its client base following a significant customer loss in Q1 2024, noted a Roth MKM research note.

AI Healthcare Co. Creates AI Pharmacy Assistant

  ()
Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) announced it will roll out a new AI (artificial intelligence) Pharmacy Assistant to support pharmacists. One analyst says the company has positioned itself as a "central go-to resource."

Showing Results: 1 to 10 of 10